Adjuvant endocrine therapy for hormone receptor-positive, HER2-negative breast cancer: risk stratification, treatment intensification, and clinical management
Year: 2026
Type: article
Abstract: The review summarizes current approaches to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative early breast cancer. It discusses clinicopathological and biological recurrence-risk factors, assessment of endocrine sensitivity, and criteria for treatment intensification. Evidence on extended endocrine therapy, ovarian suppression, aromatase inhibitors, and the addition of CDK4/6 inhibitors is presented. Particular attention is paid to prevention of bone loss, management of adverse events, drug-drug interactions, lifestyle modification, and treatment adherence. Individual treatment selection should account for the expected absolute benefit, toxicity, comorbidities, menopausal status, and patient preferences. Adjuvant endocrine therapy is viewed as a dynamic clinical management process that requires regular assessment of efficacy and safety, prevention of complications, and timely treatment modification.
Source: Medical alphabet
Institutions: Pirogov Russian National Research Medical University, Russian Cancer Research Center NN Blokhin, Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky, Ministry of Health of the Russian Federation, Nizhny Novgorod Regional Clinical Oncology Center, Chelyabinsk Regional Clinical Oncology Center, Medical Radiological Research Center, Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser, Samara Medical Institute Reaviz
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: adjuvant endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, early breast cancer, risk stratification, recurrence risk factors, endocrine sensitivity, extended endocrine therapy, ovarian suppression, aromatase inhibitors, CDK4/6 inhibitors, bone loss prevention, adverse events, drug-drug interactions, medication adherence, menopausal status, treatment intensification
Open Access status: hybrid
OpenAlex ID: W7235997026
